These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 39094986)
1. The current status and future trends of BTK inhibitor for diffuse large B cell lymphoma. Chen Q; Xu L; Lu C; Wang C; Yu L Pharmacol Res; 2024 Sep; 207():107337. PubMed ID: 39094986 [No Abstract] [Full Text] [Related]
2. Clinicopathologic and Prognostic Significance of Bruton's Tyrosine Kinase Expression in Diffuse Large B-Cell Lymphoma. Han YB; Yang JM; Kwon HJ; Lee JO; Lee JS; Paik JH Anticancer Res; 2021 Nov; 41(11):5677-5692. PubMed ID: 34732441 [TBL] [Abstract][Full Text] [Related]
3. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors. Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345 [TBL] [Abstract][Full Text] [Related]
4. Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies. da Cunha-Bang C; Niemann CU Drugs; 2018 Nov; 78(16):1653-1663. PubMed ID: 30390220 [TBL] [Abstract][Full Text] [Related]
5. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia. Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M Front Immunol; 2021; 12():766272. PubMed ID: 34912339 [TBL] [Abstract][Full Text] [Related]
7. Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines. Guo X; Yang D; Fan Z; Zhang N; Zhao B; Huang C; Wang F; Ma R; Meng M; Deng Y Eur J Med Chem; 2019 Sep; 178():767-781. PubMed ID: 31234030 [TBL] [Abstract][Full Text] [Related]
8. Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy. Taneja A; Jones J; Pittaluga S; Maric I; Farooqui M; Ahn IE; Wiestner A; Sun C Leuk Lymphoma; 2019 Feb; 60(2):519-522. PubMed ID: 29978754 [No Abstract] [Full Text] [Related]
9. Cardiovascular Toxicities of Bruton's Tyrosine Kinase Inhibitors. Pineda-Gayoso R; Alomar M; Lee DH; Fradley MG Curr Treat Options Oncol; 2020 Jun; 21(8):67. PubMed ID: 32607825 [TBL] [Abstract][Full Text] [Related]
10. The Evolving Role of Bruton's Tyrosine Kinase Inhibitors in B Cell Lymphomas. Mehra S; Nicholls M; Taylor J Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39062757 [TBL] [Abstract][Full Text] [Related]
11. Bruton's Tyrosine Kinase Inhibitors in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Meta-analysis and Systematic Review. Guo HP; Dang XL; Kang L; Liu C; Liu XW World Neurosurg; 2024 Aug; 188():161-169. PubMed ID: 38641241 [TBL] [Abstract][Full Text] [Related]
12. Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK. Wang X; Fei Y; Liu X; Zhang T; Li W; Jia X; Liu X; Qiu L; Qian Z; Zhou S; Ren X; Zhai Q; Meng B; Li L; Zhang H Aging (Albany NY); 2021 Sep; 13(17):21102-21121. PubMed ID: 34508613 [TBL] [Abstract][Full Text] [Related]
13. BTK and PI3K Inhibitors Reveal Synergistic Inhibitory Anti-Tumoral Effects in Canine Diffuse Large B-Cell Lymphoma Cells. Kong W; Sender S; Taher L; Villa-Perez S; Ma Y; Sekora A; Ruetgen BC; Brenig B; Beck J; Schuetz E; Junghanss C; Nolte I; Murua Escobar H Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884478 [TBL] [Abstract][Full Text] [Related]
14. Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma. Tanaka H; Kaneko N; Sakagami H; Matsuya T; Hiramoto M; Yamanaka Y; Mori M; Koshio H; Hirano M; Takeuchi M Leuk Res; 2020 Jan; 88():106286. PubMed ID: 31865062 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological activity of imidazole group-substituted arylaminopyrimidines (IAAPs) as potent BTK inhibitors against B-cell lymphoma and AML. Li S; Wu B; Zheng X; Wang C; Zhao J; Sun H; Sun X; Tang Z; Yuan H; Chen L; Ma X Bioorg Chem; 2021 Jan; 106():104385. PubMed ID: 33272709 [TBL] [Abstract][Full Text] [Related]
17. The role of Bruton's tyrosine kinase inhibitors in the management of mantle cell lymphoma. Hanna KS; Campbell M; Husak A; Sturm S J Oncol Pharm Pract; 2020 Jul; 26(5):1190-1199. PubMed ID: 32279595 [TBL] [Abstract][Full Text] [Related]
18. Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development. Liu J; Chen C; Wang D; Zhang J; Zhang T Eur J Med Chem; 2021 May; 217():113329. PubMed ID: 33740548 [TBL] [Abstract][Full Text] [Related]
19. Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase. Davids MS; Brown JR Future Oncol; 2014 May; 10(6):957-67. PubMed ID: 24941982 [TBL] [Abstract][Full Text] [Related]
20. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors. Lai MZ; Song PR; Dou D; Diao YY; Tong LJ; Zhang T; Xie H; Li HL; Ding J Acta Pharmacol Sin; 2020 Mar; 41(3):415-422. PubMed ID: 31316181 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]